Non-small cell lung cancer recurrent: Which Medications Are Safest? (73 Drugs Compared)
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
73 medications are used for Non-small cell lung cancer recurrent, with 3,061 combined adverse event reports. The most reported drugs for Non-small cell lung cancer recurrent are NIVOLUMAB and IPILIMUMAB.
3,061
Total Reports
73
Drugs Used
All Medications for Non-small cell lung cancer recurrent Ranked by Safety Reports
| Drug | Brand | Reports | Deaths (all) | Hosp. (all) | Death Rate |
|---|---|---|---|---|---|
| NIVOLUMAB | OPDIVO | 2,703 | 23,086 | 36,530 | 26.3% |
| IPILIMUMAB | YERVOY | 1,089 | 8,043 | 17,031 | 22.0% |
| CARBOPLATIN | Carboplatin | 350 | 12,544 | 35,869 | 14.9% |
| PEMETREXED | Pemetrexed | 228 | 3,876 | 10,697 | 16.5% |
| PACLITAXEL | PACLITAXEL PACLITAXEL | 193 | 12,030 | 31,638 | 15.6% |
| DOCETAXEL | Docetaxel | 63 | 6,068 | 13,463 | 9.3% |
| PEMBROLIZUMAB | KEYTRUDA | 58 | 15,543 | 35,472 | 18.6% |
| CISPLATIN | CISplatin | 44 | 8,387 | 17,469 | 17.7% |
| RAMUCIRUMAB | CYRAMZA | 41 | 1,444 | 2,066 | 27.0% |
| SOTORASIB | LUMAKRAS | 28 | 700 | 555 | 23.9% |
| BEVACIZUMAB | JOBEVNE | 27 | 17,498 | 23,114 | 22.4% |
| OSIMERTINIB | TAGRISSO | 27 | 12,456 | 5,277 | 44.9% |
| ERLOTINIB | Erlotinib | 17 | 6,791 | 3,693 | 30.2% |
| AFATINIB | Gilotrif | 16 | 1,346 | 2,055 | 22.1% |
| ATEZOLIZUMAB | Tecentriq Hybreza | 16 | 8,520 | 15,094 | 25.3% |
| SELPERCATINIB | RETEVMO | 14 | 160 | 342 | 14.8% |
| DURVALUMAB | IMFINZI | 13 | 5,088 | 5,968 | 29.7% |
| AMIVANTAMAB-VMJW | - | 12 | 159 | 362 | 7.9% |
| CAPMATINIB | TABRECTA | 12 | 583 | 388 | 25.3% |
| GEFITINIB | Gefitinib | 12 | 1,047 | 853 | 22.3% |